Biomedical papers, 2017 (vol. 161), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(2):179-186 | 10.5507/bp.2017.017

Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients

Libuse Noskovaa, Lenka Fialovaa, Ales Bartosb,c, Tomas Zimaa
a Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
b National Institute of Mental Health, Klecany, Czech Republic
c Department of Neurology, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic

Aims: To optimise the ELISA method for the avidity of IgG antibodies against neurofilament heavy chain (NfH) and to determine the levels and avidity of anti-NfH antibodies in patients with Alzheimer's disease (AD) and a healthy control group.

Methods: Various dilutions of sera and concentrations of urea and sodium chloride as chaotropic reagents were tested in the process of the ELISA optimisation. The levels and avidity of anti-NfH antibodies were determined in 30 patients with Alzheimer's disease and 30 age-matched cognitively normal elderly adults.

Results: Sera dilution 1:200 and urea as a chaotrope in a concentration 6 mol/L were chosen to be the most suitable for the avidity assay of anti-NfH antibodies by ELISA. The results showed no differences in either level or avidity of IgG anti-NfH antibodies between AD patients and cognitively normal persons. The levels of anti-NfH IgG antibodies inversely correlated with their avidities.

Conclusions: We optimised the ELISA method for the determination of anti-NfH antibody avidity determination which is suitable for research of anti-NfH antibody avidity in patients with neurological diseases associated with neurocytoskeletal defects. The determination of serum anti-NfH antibody avidity in AD patients seems to have limited diagnostic significance.

Keywords: Alzheimer's disease, antibodies, avidity, heavy chain of neurofilament, neurofilament

Received: December 14, 2016; Accepted: March 24, 2017; Prepublished online: April 26, 2017; Published: June 14, 2017


References

  1. Eira J, Silva CS, Sousa MM, Liz MA. The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders. Prog Neurobiol 2016;141:61-82. Go to original source... Go to PubMed...
  2. Liu Q, Xie F, Alvarado-Diaz A, Smith MA, Moreira PI, Zhu X, Perry G. Neurofilamentopathy in neurodegenerative diseases. Open Neurol J 2011;5:58-62. Go to original source... Go to PubMed...
  3. Zaffaroni M. Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci 2003;24 Suppl 5:S279-82. Go to original source... Go to PubMed...
  4. Huizinga R, Linington C, Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol 2008;29:54-60. Go to original source... Go to PubMed...
  5. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-98. Go to original source... Go to PubMed...
  6. Sigurdsson EM. Tau Immunotherapy. Neurodegener Dis 2016;16:34-8. Go to original source... Go to PubMed...
  7. Cucnik S, Kveder T, Artenjak A, Ulcova Gallova Z, Swadzba J, Musial J, Iwaniec T, Stojanovich L, Alessandri C, Valesini G, Avcin T, Cohen Tervaert JW, Rozman B, Bozic B. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus 2012;21:764-5. Go to original source... Go to PubMed...
  8. Cucnik S, Kveder T, Ulcova-Gallova Z, Swadzba J, Musial J, Valesini G, Avcin T, Rozman B, Bozic B. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus 2011;20:1166-71. Go to original source... Go to PubMed...
  9. Cui Z, Zhao MH. Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clin Immunol 2005;116:77-82. Go to original source... Go to PubMed...
  10. Woznicová V. [Immunoglobulin G avidity in infectious diseases]. [Article in Czech]. Epidemiol Mikrobiol Imunol 2004;53:4-11. Go to PubMed...
  11. Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014;32:3232-6. Go to original source... Go to PubMed...
  12. Curdt I, Praast G, Sickinger E, Schultess J, Herold I, Braun HB, Bernhardt S, Maine GT, Smith DD, Hsu S, Christ HM, Pucci D, Hausmann M, Herzogenrath J. Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG Avidity assays. J Clin Microbiol 2009;47:603-13. Go to original source... Go to PubMed...
  13. Flori P, Tardy L, Patural H, Bellete B, Varlet MN, Hafid J, Raberin H, Sung RT. Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women. Clin Diagn Lab Immunol 2004;11:669-74. Go to PubMed...
  14. Menge T, Lalive PH, von Budingen HC, Genain CP. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 2011;8:161. Go to original source... Go to PubMed...
  15. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:127-32. Go to original source... Go to PubMed...
  16. Bartos A, Fialova L, Svarcova J, Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J Neuroimmunol 2012;252:100-5. Go to original source... Go to PubMed...
  17. Soussan L, Tchernakov K, Bachar-Lavi O, Yuvan T, Wertman E, Michaelson DM. Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease. Mol Neurobiol 1994;9:83-91. Go to original source... Go to PubMed...
  18. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem 2011;418:149-51. Go to original source... Go to PubMed...
  19. Bartoš A, Zach P, Diblíková F, Tintěra J, Řípová D, Brunovský M. Visual rating of medial temporal lobe atrophy on magnetic resonance imaging in Alzheimer's disease. Psychiatrie 2007;11:49-52.
  20. Bartoš A, Čechová L, Švarcová J, Říčný J, Řípová D. Cerebrospinal fluid triplet (tau proteins and beta-amyloid) in the diagnosis of Alzheimer-Fischer disease [Likvorový triplet (tau proteiny a beta-amyloid) v diagnostice Alzheimerovy-Fischerovy nemoci]. Cesk Slov Neurol N 2012;75/108:587-94.
  21. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72.
  22. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46. Go to original source... Go to PubMed...
  23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. Go to original source... Go to PubMed...
  24. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9. Go to original source... Go to PubMed...
  25. Bartoš A, Raisová M. The Mini-Mental State Examination (MMSE) - Czech norms and cut-offs for mild dementia and mild cognitive impairment due to Alzheimer disease. Dementia and Geriatric Cognitive Disorders 2016;42:50-7. Go to original source... Go to PubMed...
  26. Povova J, Ambroz P, Bar M, Pavukova V, Sery O, Tomaskova H, Janout V. Epidemiological of and risk factors for Alzheimer's disease: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:108-14. Go to original source... Go to PubMed...
  27. Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002;58:1372-81. Go to original source... Go to PubMed...
  28. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007;116:100-7. Go to original source... Go to PubMed...
  29. Fialova L, Svarcova J, Bartos A, Malbohan I. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol (Praha) 2012;57:415-9. Go to original source... Go to PubMed...
  30. Cucnik S, Bozic B, Kveder T, Tomsic M, Rozman B. Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Ann N Y Acad Sci 2005;1051:141-7. Go to original source... Go to PubMed...
  31. Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods 2013;387:36-42. Go to original source... Go to PubMed...
  32. Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986;86:83-7. Go to original source... Go to PubMed...
  33. Gharavi A, Reiber H. Affinity and avidity of autoantibodies. In: Peter J, Shoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier, 1996: 13-23.
  34. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478-82. Go to original source... Go to PubMed...
  35. Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012;26:73-80. Go to original source... Go to PubMed...
  36. D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses 2005;64:458-63. Go to original source... Go to PubMed...
  37. Colasanti T, Barbati C, Rosano G, Malorni W, Ortona E. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev 2010;9:807-11. Go to original source... Go to PubMed...
  38. Papuc E, Kurys-Denis E, Krupski W, Tatara M, Rejdak K. Can Antibodies Against Glial Derived Antigens be Early Biomarkers of Hippocampal Demyelination and Memory Loss in Alzheimer's Disease? J Alzheimers Dis 2015;48:115-21. Go to original source... Go to PubMed...
  39. Ishida K, Kaneko K, Kubota T, Itoh Y, Miyatake T, Matsushita M, Yamada M. Identification and characterization of an anti-glial fibrillary acidic protein antibody with a unique specificity in a demented patient with an autoimmune disorder. J Neurol Sci 1997;151:41-8. Go to original source... Go to PubMed...
  40. Mecocci P, Parnetti L, Donato R, Santucci C, Santucci A, Cadini D, Foa E, Cecchetti R, Senin U. Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain Behav Immun 1992;6:286-92. Go to original source... Go to PubMed...
  41. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006;410:90-3. Go to original source... Go to PubMed...
  42. Tanaka J, Nakamura K, Takeda M, Tada K, Suzuki H, Morita H, Okado T, Hariguchi S, Nishimura T. Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol Scand 1989;80:554-60. Go to original source... Go to PubMed...
  43. d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013;8:e62402. Go to original source... Go to PubMed...
  44. Chapman J, Alroy G, Weiss Z, Faigon M, Feldon J, Michaelson DM. Anti-neuronal antibodies similar to those found in Alzheimer's disease induce memory dysfunction in rats. Neuroscience 1991;40:297-305. Go to original source... Go to PubMed...
  45. Oron L, Dubovik V, Novitsky L, Eilam D, Michaelson DM. Animal model and in vitro studies of anti neurofilament antibodies mediated neurodegeneration in Alzheimer's disease. J Neural Transm Suppl 1997;49:77-84. Go to PubMed...
  46. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007;254:20-5. Go to original source... Go to PubMed...
  47. Totland C, Aarseth J, Vedeler C. Hu and Yo antibodies have heterogeneous avidity. J Neuroimmunol 2007;185:162-7. Go to original source... Go to PubMed...
  48. Bozic B, Cucnik S, Kveder T, Rozman B. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun Rev 2005;4:303-8. Go to original source... Go to PubMed...
  49. Božič B, Čučnik S, Kveder T, Rozman B. Affinity and avidity of autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, eds. Autoantibodies. Amsterdam: Elsevier, 2007: 21-28. Go to original source...
  50. Schlosser M, Koczwara K, Kenk H, Strebelow M, Rjasanowski I, Wassmuth R, Achenbach P, Ziegler AG, Bonifacio E. In insulin-autoantibody-positive children from the general population, antibody affinity identifies those at high and low risk. Diabetologia 2005;48:1830-2. Go to original source... Go to PubMed...
  51. Cao Z, Lv J, Quan W. Low avidity and level of serum anti-Abeta antibodies in patients with cerebral amyloid angiopathy-related cerebral hemorrhage. Int J Neurosci 2010;120:760-4. Go to original source... Go to PubMed...